2 BADAN KOORDINASI PENANAMAN MODAL 3

Indonesia merupakan pasar obat potensial. Berdasarkan data dari Badan Pengawas
Obat dan Makanan (BPOM, 2016), jumlah industri farmasi saat ini sebanyak 208
perusahaan, terdiri dari 4 BUMN, 35 multinasional dan 169 swasta nasional Indonesia.
Mayoritas industri farmasi di Indonesia masih bergerak pada industri formulasi atau
industri pembuatan obat jadi. Hal ini yang menyebabkan kebutuhan impor bahan
baku pembuatan obat menjadi besar. Rata-rata pasar farmasi di Indonesia tumbuh
12-13% per tahun. Pada level ASEAN, pasar farmasi Indonesia mencapai 27% total
pasar farmasi ASEAN, dari jumlah tersebut 70% pangsa pasar dikuasai oleh industri
nasional. Tahun 2015 pasar farmasi di Indonesia bernilai sekitar Rp. 60 Triliun dan
diperkirakan terus meningkat sejalan dengan potensi pertumbuhan penduduk,
meningkatnya kesadaran masyarakat akan kesehatan, pendapatan per kapita dan
akses layanan kesehatan (BPJS).

Potensi pasar obat-obatan di Indonesia yang besar mendorong laju investasi di

sektor farmasi. Hal ini terlihat dari total realisasi investasi industri farmasi periode
2010 sampai dengan Kuartal III Tahun 2016 yang mencapai Rp. 9,2 Triliun. Total nilai
realisasi investasi ini berasal dari investasi asing sebesar Rp. 5,3 Triliun dan investasi
GAMBARAN UMUM domestik sebesar Rp. 3,9 Triliun (BKPM, 2016).

INDUSTRI BAHAN BAKU OBAT DI INDONESIA

PERKEMBANGAN INVESTASI INDUSTRI FARMASI DI INDONESIA
2010 - TW3 2016, RP MILYAR

Sumber: BKPM, 2016

BUKU KAJIAN T.A. 2016

4 BADAN KOORDINASI PENANAMAN MODAL
Untuk sebaran realisasi investasi industri farmasi periode 2010 sampai dengan
Kuartal III Tahun 2016 masih didominasi Pulau Jawa. Realisasi investasi terbesar di
Provinsi Jawa Barat yakni mencapai Rp. 5,5 Triliun diikuti Jawa Timur sebesar Rp. 2,6
Triliun. Jepang merupakan negara asal investasi dengan realisasi terbesar, yakni Rp.
2 Triliun, diikuti oleh Jerman dan Amerika Serikat.
Struktur industri farmasi Indonesia belum optimal (terbatas formulasi). Hampir
90% bahan baku yang digunakan di industri farmasi adalah impor. Berdasarkan data
dari Kementerian Perindustrian, 2016, saat ini Indonesia mengimpor bahan baku obat
terbanyak dari Tiongkok, India, dan kawasan Eropa. Tiongkok masih menjadi negara
sumber pemasok terbesar kebutuhan bahan baku obat Indonesia, yakni sekitar Rp
6,84 triliun (60%), India di posisi kedua Rp 3,42 triliun (30%), dan Eropa Rp 1,4 triliun
(10%). Ketergantungan yang teramat tinggi pada bahan baku impor menjadikan
industri farmasi Indonesia sangat rawan, apalagi dengan keadaan pelemahan kurs
rupiah yang akan mendongkrak biaya produksi. Keseimbangan antara neraca impor
dengan ekpor disebabkan karena bahan baku lokal juga diekspor. Sedangkan
Indonesia, meski 90% bahan bakunya impor, dengan bahan baku lokal sejumlah 10
% yang belum bisa diekspor.
Dari grafik di bawah ini, pasar antibiotik selain golongan amoksisilin, ampisilin,
tetrasiklin, kloramfenikol, eritromisin Indonesia menunjukkan nilai terbesar. Antibiotik
10 BESAR IMPOR BAHAN BAKU OBAT TERBESAR TAHUN 2014 (US$)
Sumber : BPS, 2015
5
golongan sefalosporin termasuk didalamnya, yang berarti kebutuhan Sefalosporin
sangat tinggi di Indonesia (tidak hanya di Indonesia, tetapi juga di dunia), sehingga
perlu dikembangkan industri bahan baku Sefalosporin dan pemenuhan pasokan
pasar Sefalosporin di Indonesia.
Sefalosporin adalah kelas antibiotik β-laktam yang diturunkan dari fungus
Acremonium. Saat ini Sefalosporin relatif banyak digunakan dibandingkan antibiotik
lainnya, karena kemungkinan terjadinya alergi kecil, memiliki sifat meracuni yang
rendah dan merupakan antibiotik dengan cakupan luas (broad spectrum). Di
Indonesia juga banyak sekali digunakan sefalosporin bahkan untuk penyakit kronis.
Hingga saat ini antibiotik broad spectrum Sefalosporin telah memasuki Generasi
Ke-5. Yang paling banyak digunakan di Indonesia adalah Sefalosorin Generasi ke-
3, efektif untuk menangani bakteri Enterobacteriaceae termasuk strain penghasil
penisilinase. Obat oral generik yang tersedia di Indonesia, misalnya: Cefixime dan
Cefpodoxime. PT. Kimia Farma Persero Tbk. yang merupakan pioner industri farmasi
di Indonesia saat ini akan mengembangkan bahan baku obat antibiotik, khususnya
Sefalosporin, dengan memanfaatkan bahan baku lokal yang melimpah.
Dalam mengembangkan bahan baku antibiotik sefalosporin, Kimia Farma akan
mendirikan pabrik melalui 2 (dua) tahap yaitu tahap pertama membangun pabrik
untuk mengolah raw material menjadi intermediate material, dilanjutkan tahap kedua
membangun pabrik untuk mengolah intermediate material menjadi bahan baku
obat Chephalosporin (ada 50 item turunan Cephalosporin). Pabrik kedua ini yang
dinamakan industri Active Pharmaceutical Ingredient (API), produk dari pabrik ini
yang akan dipakai oleh industri farmasi untuk memproduksi antibiotik sefalosporin.
Kimia Farma menginisiasi pabrik API di Indonesia dan membuka peluang bagi
perusahaan lain yang akan mengembangkan API di Indonesia.
Baru-baru ini pula Kimia Farma bekerjasama dengan Universitas Gadjah Mada (UGM)
dan Kementerian Perindustrian akan mengembangkan bahan baku Parasetamol, yang
saat ini masih dalam tahap penelitian oleh UGM. Kementerian Perindustrian akan
membantu penyediaan bahan dasar kimianya, sementara Kimia Farma yang akan
mengembangkan, memproduksi hingga memasarkannya. Parasetamol termasuk
bahan baku obat yang paling banyak dikonsumsi dengan kebutuhan di Indonesia
mencapai 4.500 Ton per tahun. Proyek ini masih membuka peluang investasi bagi
swasta untuk bekerjasama dengan Kimia Farma dalam mengembangkan bahan
baku parasetamol di Indonesia.
BUKU KAJIAN T.A. 2016
6 BADAN KOORDINASI PENANAMAN MODAL
Dengan rencana pembangunan pabrik Bahan Baku Obat yang dilakukan oleh
Perseroan ini diharapkan ke depan dapat mengurangi ketergantungan akan impor
bahan baku obat sehingga akan memberikan dampak positif bagi kemajuan industri
farmasi di Indonesia.
Industri farmasi nasional harus melakukan transformasi, bukan hanya sebagai industri
farmasi formulasi namun ke depan mampu menjadi industri farmasi berbasiskan riset
dan pengembangan serta manufaktur yang memiliki kemampuan untuk memproduksi
bahan baku secara mandiri. Dengan demikian, mendukung terciptanya industri
farmasi yang terintegrasi, mulai dari produksi bahan baku, penguasaan teknologi
dan peningkatan  ekspor.
Untuk menarik investasi dan membuat investasi yang sudah ada memiliki keuntungan,
pasar yang besar harus disertai dengan daya beli yang tinggi, dan iklim bisnis serta
investasi yang kondusif. Perubahan yang signifikan dan agresif diperlukan karena
bila tidak dilakukan maka Indonesia akan tertinggal. Saat ini, Pemerintah Indonesia
tengah berupaya untuk mendorong tumbuhnya industri hulu farmasi, yakni industri
bahan baku obat. Keberadaan sektor industri bahan baku obat dinilai penting
sebagai industri substitusi impor bahan baku obat yang sangat tinggi. Impor
7
yang tinggi juga ikut menekan neraca perdagangan dan defisit transaksi berjalan.
Dengan demikian, sangatlah penting Pemerintah mendorong kemandirian industri
farmasi dalam negeri dalam upaya untuk menekan harga obat dan mengurangi
ketergantungan bahan baku obat impor serta menghemat devisa negara. Kebijakan
yang mendukung Kemandirian Bahan Baku Obat Nasional yakni :
• Peraturan Menteri Kesehatan Nomor 87 Tahun 2013 tentang Peta Jalan
Pengembangan Industri Bahan Baku Obat.
• Peraturan Pemerintah Nomor 14 Tahun 2015 tentang Rencana Induk
Pembangunan Industri Nasional (RIPIN) Tahun 2015-2035  Industri Farmasi,
Kosmetik dan Alat Kesehatan menjadi salah satu industri andalan prioritas.
• Paket Kebijakan Ekonomi XI (poin. 4 ) Pengembangan Industri Farmasi dan Alat
Kesehatan, salah satunya dengan membuka kepemilikan asing hingga 100%
untuk industri bahan baku obat sebagaimana tertuang dalam Peraturan Presiden
Nomor 44 Tahun 2016. Sebelumnya, ketentuan porsi kepemilikan asing untuk
industri bahan baku obat maksimal sebesar 85% berdasarkan Peraturan Presiden
Nomor 39 Tahun 2014. Melalui kebijakan baru ini, Pemerintah berharap dapat
menarik investasi lebih besar ke industri bahan baku obat. Kebijakan lainnya
yaitu kebijakan fiskal berupa pembebasan bea masuk, Tax Holiday dan Tax
Allowance.
• Instruksi Presiden No. 6 Tahun 2016 tentang Percepatan Pengembangan Industri
Farmasi dan Alat Kesehatan  melibatkan beberapa instansi terkait termasuk
Badan Koordinasi Penanaman Modal (BKPM).
Buku ini berisi profil proyek (Investment Project Ready to Offer / I-PRO) tentang
bahan baku obat (Active Pharmaceutical Ingredients / API) di PT. Kimia Farma
Persero Tbk. yang meliputi bahan baku antibiotik Sefalosporin dan rencana
awal pengembangan bahan baku Parasetamol. Kami mengharapkan buku ini
dapat memudahkan para calon investor memperoleh informasi dalam mengambil
keputusan berinvestasi di bidang bahan baku obat.
BUKU KAJIAN T.A. 2016
8 BADAN KOORDINASI PENANAMAN MODAL 9

ACTIVE PHARMACEUTICAL INGREDIENTS (API) PROJECT

AT PT. KIMIA FARMA (PERSERO) TBK.

INVESTMENT PROJECT READY TO OFFER (I-PRO) 2016

BUKU KAJIAN T.A. 2016

10 BADAN KOORDINASI PENANAMAN MODAL 11

TABLE OF CONTENTS

1. INTRODUCTION

2. ACTIVE PHARMACEUTICAL INGREDIENTS (API)

PROJECT AT PT. KIMIA FARMA (PERSERO) TBK.

3. GOVERNMENT POLICY TOWARD PHARMACEUTICAL

INDUSTRY

4. INVESTMENT INCENTIVES

5. INVESTMENT NEGATIVE LIST

6. INVESTOR RELATION

LAPORAN TAHUNAN 2016

12 BADAN KOORDINASI PENANAMAN MODAL 13
Dear Investors,

Indonesia recognizes the importance of private sector investment to achieve sustainable

economic growth, employment creation, development of strategic national resources, transfer
and implementation of competitive technology and technical skills, export growth and
improved balance of payments.

President Joko Widodo has issued several economic reform packages with the overall aim of
boosting economic growth and attract investment. Whether new business development or
business expansion, it truly is an exciting time to invest in Indonesia as investors can expect
streamlined regulations, simplified and faster licensing, as well as attractive incentives. One
of the priority sectors of the Government policies is to develop the domestic production of
pharmaceutical raw materials. The presence of pharmaceutical raw materials industry sector
is considered important as import substitution industry. Approximately 90% of pharmaceutical
raw materials come from abroad to meet the domestic production of finished drugs. High
import also put pressure on the trade balance and the current account deficit.

As the country with the 4th largest population in the world, Indonesia is the largest
pharmaceutical market in the ASEAN region. The Indonesian pharmaceutical market reached
27% of total ASEAN market where 70% was dominated by the local industry. The average
pharmaceutical market in Indonesia is growing 12-13% per year. In the future the pharmaceutical
industry in Indonesia will continue to grow rapidly in line with population growth potential,
increased drug needs, income per capita and health services. The biggest Indonesian
state-owned pharmaceutical company PT. Kimia Farma (Persero) Tbk. plans to build several
Active Pharmaceutical Ingredients (API) plants to meet raw materials demands and reduce
dependence on imported raw materials. It is an excellent investment opportunity as Indonesia
has a wealth of biological resources to develop pharmaceutical raw material industries and
Indonesia’s growing market. PT. Kimia Farma (Persero) Tbk. welcome investor interest in
investing, especially as the Government is encourage efforts to develop the pharmaceutical
raw material industry in Indonesia. Furthermore now Government allows 100% foreign equity
ownership for the pharmaceutical raw material industry.

Investing in Indonesia is the right business decision. I invite you to optimize the abundant
advantages of producing and manufacturing in our remarkable country. We are just at the
beginning of a promising new era and we look forward to partnering with you.

Thomas T. Lembong
Chairman of Investment Coordinating Board Republic of Indonesia

BUKU KAJIAN T.A. 2016

14 BADAN KOORDINASI PENANAMAN MODAL 15

ACTIVE PHARMACEUTICAL INGREDIENTS (API) PROJECT

AT PT. KIMIA FARMA (PERSERO) TBK.

BUKU KAJIAN T.A. 2016

16 BADAN KOORDINASI PENANAMAN MODAL 17
PT. KIMIA FARMA • Kimia Farma has 4 subsidiaries :
(PERSERO) TBK.
COMPANY PROFILE Entity Main Business
PT. Kimia Farma (Persero) Tbk (Holding) Manufacture, R&D, Marketing

PT. Kimia Farma Trading & Distribution Trade and Distribution

PT. Kimia Farma Apotek Retail, Health Clinic, Laboratory Clinic

PT. Sinkona Indonesia Lestari Quinine Factory and Marketing

Kimia Farma is the first pharmaceutical industry
PT. Kimia Farma Sungwun Pharmacopia Chemical & API manufacture
company in Indonesia established by the Dutch Indies
Government in 1817. The name of this company was
originally NV Chemicalien Handle Rathkamp & Co. In • Its plants are located in Jakarta, Bandung, Semarang, Jombang and Medan, Indonesia.
1958, when the Indonesian Government nationalized
all of Dutch Companies, status of the Company was • 2015 – Total Sales : Rp. 4,86 Triliun
transformed as State Company. In 1969, several Net profit : Rp. 253 Miliar
State Companies were merged into one Company of
Pharmaceutical and Medical Devices State Company
or known as PNF Bhinneka Kimia Farma. In 1971,
pursuant to Government Act No. 16 of 1971, status as
state company was transformed into a limited liability
company, named PT. Kimia Farma (Persero).

On July 4, 2001, PT. Kimia Farma (Persero) changed its

status into public entity, PT Kimia Farma (Persero) Tbk.
With years of experience, the Company has evolved
into a Company with integrated health services in
Indonesia. The Company has larger share on the
nation development, especially health development
for Indonesian society.

• Some of its products are generic drugs, over-the-

counter (OTC) drugs, herbal medicines, branded
ethical drugs, antiretroviral drugs, contraceptives,
cosmetic & body care and raw materials.

BUKU KAJIAN T.A. 2016

18 BADAN KOORDINASI PENANAMAN MODAL 19
ACTIVE
Development of pharmaceutical raw materials in the modern treatment of bacterial infections. 7-ACA is a core intermediate for over 50
PHARMACEUTICAL
are Government’s top priority in order to reduce cephalosporin downstream API and formulated finished drugs. Furthermore this document
INGREDIENTS (API)
Indonesian pharmaceutical industry’s dependence on also provide brief information about other API project in Kimia Farma currently, which
PROJECT
imported raw materials. is project plan of Paracetamol raw material development cooperate with Gadjah Mada
AT PT. KIMIA FARMA
University and Ministry of Industry.
(PERSERO) TBK
Kimia Farma as a pioneer in the pharmaceutical
industry of Indonesia has set strategies to cut
dependency on imported raw materials as well KIMIA FARMA API LIST PROJECT
as to support Government initiative on National
Pharmaceutical Raw Material Self-Fulfillment
(Kemandirian Bahan Baku Obat Nasional). In the
future, raw material importing will continue to

2015 - 2017
decline that will reduce strategic and financial risks
encountered by the company as well as expected
to bring possitive contribution for Indonesian
pharmaceutical industry development.

Pharmaceutical raw material including Active

Pharmaceutical Ingredient (API) and Excipient.
Highlighted in this document is API project at Kimia
Farma in cooperation with Agency for Assessment
and Application of Technology (BPPT), specifically
production of Antibiotic Cephalosporin C (7-ACA).
Cephalosporins are one of most widely used drug
classes in worldwide. They have an important role

BUKU KAJIAN T.A. 2016

20 BADAN KOORDINASI PENANAMAN MODAL 21

TOP LEADING IMPORT OF API (%) WHY WE SHOULD DEVELOP CEPHALOSPORIN?

• Indonesia imports raw material for the pharmaceutical industry amounted to 95 percent.

Choline 5%
• Based on the statistic in 2014, Cephalosporin dominated the API import at 19 percent.
Other Vitamin&Derivatives 7%

Plasma Protein 7% • Actually, BPPT researched cephalosporin in 1991, but it has not been developing up to
now in Indonesia. On the other hand, China, that started this research at the same time
Calcium Carbonate 8%
with Indonesia, has fast growth in cephalosporin.
Vitamin C 8%

Vitamin E • Indonesian people need cephalosporin amounted to 100 ton/year.

10%

Calcium hydrogenothphosphate 10%

• China, Japan, South Korea are countries that use cephalosporin more than the other API
Paracetamol, salicylamide 10% (almost 70%). During this time, Indonesia imports cephalosporin from China about 60
percent.
Amoxycillin 17%

Cephalosporin 19% • KIMIA FARMA plans to build the first cephalosporin industry in Indonesia. It is expected
to reduce import of pharmaceutical raw material up to 20-30 percent.
Source: Statistic Indonesia, 2014
• Indonesia has pharmaceutical resources potential which can be used as an alternative for
API starting material.

BUKU KAJIAN T.A. 2016

22 BADAN KOORDINASI PENANAMAN MODAL 23

CEPHALOSPORIN PROJECT PROFILE CEFIXIME (ANTIBIOTIC CEPHALOSPORIN C) MANUFACTURING PROCESS

CHEMICAL PHARMACEUTICAL CEFIXIME

API INDUSTRY
INDUSTRY INDUSTRY TABLETS

Name of Project : Cephalosporin Project

API STARTING MATERIAL RAW MATERIAL CEFIXIME API
7-ACA
Status : FDI (PT. Kimia Farma, PT. SungwunPharmacopia Indonesia)
1. SOYBEAN OIL
2. PEANUTS
Business Field : API Industry 3. SAGO SOLVENT EXCIPIENT
4. YAM TOLUENE TOLUENE
5. CORN OIL ETHANOL ETHANOL
Location : Cikarang, West Java 6. TUNA FISH
7. AMMONIA
8. SUGAR SOLVENT
FERMENTATION
Product/Capacity : Cephalosporin C (7-ACA) / 500 ton pa 9. SORBITOL
PROCESS AQUA DM
10. ETC

Market : 80% Export, 20% Domestic

TABLETS / CAPSULES
FERMENTATION PROCESS
Investment : IDR 800 - 1,000 billion PROCESS CEFIXIME
API
Financing Scheme : Business to Business

Land Area : 3 Ha
7 - ACA
Support Required : Masterlist Electricity (5 MW)

Source: PT. Kimia Farma Sungwun Pharmacopia, 2016 Source: PT. Kimia Farma Sungwun Pharmacopia, 2016

BUKU KAJIAN T.A. 2016

24 BADAN KOORDINASI PENANAMAN MODAL 25

PROGRESS OF Currently land area availability is 12 Ha located in the strategic location in Lippo Cikarang,
CEPHALOSPORIN West Java.
PROJECT
AT KIMIA FARMA

On June 2016 Kimia Farma, BPPT and Sungwun

Pharmacopia (Korea) signed a MoU on development
of active pharmaceutical ingredients plant in
Indonesia, namely antibiotic Cephalosporin.

The feasibility study is targeted to begin in November 2016 and completed in April 2017.

BUKU KAJIAN T.A. 2016

26 BADAN KOORDINASI PENANAMAN MODAL 27
CEPHALOSPORIN PROJECT SCHEDULE

2017 2018 2019 2020

ACTIVITY
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Konstruksi Bangunan

Conceptual Design

Design Construction Consultan

Consultant Building Construction - Bidding

Pembangunan Fisik Pabrik Cephalosphorin

Konstruksi Fasilitas

Mechanical Engeenering Design

Tender Pengadaan Fasilitas - URS Bidding

Contract and Purchase Order - Machine

Installation Machine (at site)

Production

Pilot Production

2016 2017
ACTIVITY
Jan Feb Mar Apr May Jun Jul Ags Sep Otk Nov Dec Jan Feb Mar Apr May Jun Jul Ags Sep Otk Nov Dec

Development

BPPT - Kimia Farrna - Sungwun Korea

Colaboration Scheme

Draft MoU

Signing Mou

Structure

Making R&D System

Organization of Project Team

Sungwun Korea - Org of Project Team

BPPT+KF - Org of Project Team Verification

Feasibility Study

Feasibility Repon

Bussiness Approval and Reviews

Contract

Source: PT. Kimia Farma Sungwun Pharmacopia, 2016

BUKU KAJIAN T.A. 2016

28 BADAN KOORDINASI PENANAMAN MODAL 29

On July 20, 2016, PT. Kimia Farma (Persero) Tbk., the

Ministry of Industry and the University of Gajah Mada
PARACETAMOL RAW (UGM) signed a MoU agreement of Development of
MATERIAL Paracetamol Raw Material.
DEVELOPMENT
AT PT. KIMIA FARMA UGM will conduct research into paracetamol raw
(PERSERO) TBK. materials. Kimia Farma are ready to assist in terms of
production and marketing. The Ministry of Industry will
help provide basic chemical materials. Paracetamol
is the pharmaceutical raw materials most widely

the Ministry of Industry will deliver all chemicals and other reagents to UGM to be used as
base material in the research and manufacture of Paracetamol raw materials. Kimia Farma also
supports the activity of pilot scale production of Paracetamol raw materials by using the results
of UGM research.
 
The availability of Paracetamol raw materials is phenol which may be made of benzene where
the availability of benzene in Indonesia is very abundant i.e. 123,000 tons per year (source:
Ministry of Industry, 2015).

consumed in Indonesia. The need for paracetamols in
Indonesia reaches 4,500 tonnes per year. Paracetamol
is mostly used as antipyretic & analgesic raw material
medicine.
Kimia Farma is optimistic that this project will help the Government program on National
Pharmaceutical Raw Material Self-Fulfillment (Kemandirian Bahan Baku Obat Nasional), so
that the future will reduce dependence on imported pharmaceutical raw materials. It may
give an opportunity for private companies in partnership with Kimia Farma to develop
Paracetamol raw material.

UGM Involvement in conducting research on

paracetamol starting from the manufacture of
para-aminophenol (PAF) until the manufacture of
paracetamol raw materials in laboratory scale and

BUKU KAJIAN T.A. 2016

30 BADAN KOORDINASI PENANAMAN MODAL 31

GOVERNMENT POLICY TOWARD PHARMACEUTICAL

INDUSTRY

BUKU KAJIAN T.A. 2016

32 BADAN KOORDINASI PENANAMAN MODAL 33
PHARMACEUTICAL
RAW MATERIALS
DEVELOPMENT

Health Ministry Regulation No. 87/2013 concerning

Roadmap of Pharmaceutical Raw Material

SHORT TERM MID TERM LONG TERM

(1 - 3 YEAR) (3 - 5 YEAR) (6 - 10 YEAR)

CHEMICAL PRODUCT

1. PARACETAMOL 1. CEPHALOSPHORIN NEW GENERATION ANTIBIOTICS

2. DFA III DERIVATIVES
3. PENICILLIN 2. AMYLUM
4. CITRIC ACID
5. PHARMACEUTICAL SALT
6. ARTEMISININ
7. RADIOPHARMACEUTICALS

BIOLOGIC MEDICAL PRODUCT

1. SABIN-IPV 1. TB RECOMBINANT 1. DENGUE
2. ROTAVIRUS (ORAL) 2. PNEUMOCOCCAL 2. MALARIA
3. PENTAVALENT 3. ERITHROPOIETIN 3. DNA VACCINE
4. SEASONAL FLU 4. ALBUMIN 4. HIV/AIDS
5. HPV

BUKU KAJIAN T.A. 2016

34 BADAN KOORDINASI PENANAMAN MODAL 35
PHARMACEUTICAL • Glucose Pharmaceutical Grade (for infusion)
INDUSTRY
DEVELOPMENT • Amoxicillin
PROGRAM
2015 -2019 • Glimepiride

• Parasetamol

• Biologic product
Government Regulation No. 14/2015 concerning
Master Plan of National Industry Development • Vaccine
2015 – 2035
• Herbal/natural product

NO. DEVELOPMENT PROGRAM • Additional raw material in drugs manufacturing (excipient)

Improve the mastery of pharmaceutical industry process technology and product engineering through
1
integrated research and development

2 Facilitate pharmaceutical raw material industry for import substitution

Encourage the increasing use of local product, including improving linkages between small, medium and
3 large industries

Strengthen the infrastructure for the implementation of the Indonesian Pharmacopoeia for pharmaceutical
4
industry

5 Develop upstream petrochemical sector to reduce raw material dependence

6 Develop research and manufacturing of standardized and integrated biotechnology and herbal product

7 Build competency and capability of pharmaceutical research for biotechnology and herbal product

8 Conduct technology mastery and develop international standard manufacturing capability

9 Improve clinical trials ability

Developed commodity 2015 – 2019 :

• Herbal preparation

• Sodium Chloride Pharmaceutical Grade

• Cephalosporin derivatives

• Amlodipine

BUKU KAJIAN T.A. 2016

36 BADAN KOORDINASI PENANAMAN MODAL 37

INVESTMENT INCENTIVE

BUKU KAJIAN T.A. 2016

38 BADAN KOORDINASI PENANAMAN MODAL 39

FISCAL INCENTIVE Investment Priority Service

Non Fiscal Incentive for Investment

NO REQUIREMENTS

NO MINIMUM INVESTMENTS OR WORKERS IS REQUIRED. INVESTORS IN ALL

INDUSTRIES CAN IMEDIATELY START THEIR PROJECT CONSTRUCTION WITHIN
SELECTED INDUSTRIAL PARKS. PERMITS CAN BE OBTAINED IN PARALLEL.

BUKU KAJIAN T.A. 2016

40 BADAN KOORDINASI PENANAMAN MODAL 41

BUKU KAJIAN T.A. 2016

42 BADAN KOORDINASI PENANAMAN MODAL 43

INVESTMENT NEGATIVE LIST

BUKU KAJIAN T.A. 2016

44 BADAN KOORDINASI PENANAMAN MODAL 45

INVESTMENT NEGATIVE LIST

Presidential Regulation of The Republic of Indonesia No. 44/2016 Concerning

List of Business Fields Closed to Investment and Business Fields Open With
Conditions to Investment

Health sector

Business Field ISIC Conditions

Patent medicine Foreign capital ownership
21012
Industry : Max 85%
Pharmaceutical Foreign capital ownership
21011
raw material : Max 100%
Open To Foreign
Industry
Investment
Medical Foreign capital ownership
Equipment : Max 67%
71205
Testing
Institution
Narcotic Subject to a special
manufacturer license from the Ministry
Subject to a 21012
(pharmaceutical of Health
special license industry)
from the Ministry
of Health Narcotic Subject to a special
pharmaceutical 46693 license from the Ministry
wholesaler of Health
Traditional Domestic capital : 100%
medicine 21022
processing
Pharmaceutical Domestic capital : 100%
100% Domestic
raw material
Capital 46693
wholesale
business
Pharmacy 47722 Domestic capital : 100%
drugstore 47723

BUKU KAJIAN T.A. 2016

46 BADAN KOORDINASI PENANAMAN MODAL 47

INVESTOR RELATIONS

Questions?

We are ready to help you make the right decision to join API Project at PT. Kimia Farma
(Persero) Tbk.
Please contact us at:

Indonesia Investment Coordinating Board

Investor Relation Unit
Jl. Jend. Gatot Soebroto No. 44, Jakarta 12190
Phone : +62-21 52880456
Fax : +62-21 52880389
Email : info@bkpm.go.id
Web : www.bkpm.go.id

Martina Navratilova
Chemical Industry Sub Directorate
Phone : +62-21 5252008 ext 3815
Mobile : +6281295464698
Email : martina.navratilova@bkpm.go.id

Verdi Budidarmo
President Director
Mobile : +62811864250
Email : vbudidarmo@kimiafarma.co.id
PT. Kimia Farma Sungwun Pharmacopia
Kompleks Majapahit Permai Blok A-101
Jl. Majapahit Raya
Jakarta
www.kimiafarma.co.id

BUKU KAJIAN T.A. 2016